Clinical Trial Update: Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of MBL-HCV1 with direct-acting antivirals in liver transplant patients with hepatitis C was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MBL-HCV1

Snippet

Sponsor: MassBiologics | Conditions: Hepatitis C Infection | Phase 2 | Status: TERMINATED | Results posted: 2021-02-05